Scancell Enters Research Collaboration With immatics biotechnologies GmbH To Develop Novel Immunobody(R) Vaccines For Colorectal Cancer

Published: Jun 29, 2010

NOTTINGHAM, UK--(BUSINESS WIRE)--Scancell Holdings Plc, (PLUS:SCLP), the developer of therapeutic cancer vaccines, today announces a research collaboration with immatics biotechnologies GmbH (“immatics”) to explore the development of novel ImmunoBody® vaccines for colorectal cancer.

Back to news